RESEARCH
PUBLICATIONS
NEXTBIO COMMUNITY
Results presented below are derived from data collected from over 475 news feeds.
Click on one of these terms to refine your search
1 to 10 of 244 stories
ImmuPharma's shares dropped 19 percent following the announcement that a Phase II study of the potential lupus treatment Lupuzor did not reach statistical significance. But CEO Dimitri Dimitriou claims that the market has misinterpreted the study results, and that the subset of patien…
Molecule identified in lab mice may cause autoimmune disease
Positive results from two late stage trials offer hope for sufferers of the autoimmune disease lupus
Human Genome and GlaxoSmithKline said their experimental drug Benlysta met the goal of a second late-stage study in treating lupus, making it likely to be the first treatment in decades for the hard-to-treat autoimmune disease.
The first in a new class of experimental drugs that targets the disease process involved in lupus beat out standard treatment in a large clinical trial, researchers say.
Rockville-based Human Genome Sciences announced Monday that its experimental lupus drug has completed its final round of testing at a higher dose and will be headed to the Food and Drug Administration for approval.
Human Genome Sciences said early Monday that its experimental drug to treat lupus was effective in its second big clinical trial.
People with systemic lupus erythematosus (SLE) have a more than twofold increased risk of cardiovascular disease, according to a new study. Source: Reuters Health Related MedlinePlus Topics: ,
At least a dozen or more genes may help explain what causes lupus, according to two new studies.
Molecule identified in lab mice may cause autoimmune diseaseSource: HealthDay Related MedlinePlus Topic: